Looking beyond PPHN: The unmet challenge of chronic progressive pulmonary hypertension in the newborn

Candice D. Fike, Judy L. Aschner

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Infants with forms of pulmonary hypertension (PH) that persist or develop beyond the first week of life are an understudied group of patients with up to 40%–60% mortality. The clinical management of the progressive PH that develops in these infants is challenging because of the nonspecific signs and symptoms of clinical presentation, the limited diagnostic sensitivity of standard echocardiographic techniques, and the lack of proven therapies. The signaling mechanisms that underlie the structural and functional abnormalities in the pulmonary circulation of these infants are not yet clear. The ability to improve outcomes for these patients awaits technological advances to improve diagnostic capabilities and therapeutic discoveries made in basic science laboratories that can be tested in randomized clinical trials.

Original languageEnglish (US)
Pages (from-to)454-466
Number of pages13
JournalPulmonary Circulation
Volume3
Issue number3
DOIs
StatePublished - Sep 1 2013
Externally publishedYes

Fingerprint

Pulmonary Hypertension
Newborn Infant
Pulmonary Circulation
Signs and Symptoms
Randomized Controlled Trials
Mortality
Therapeutics

Keywords

  • Bronchopulmonary dysplasia
  • Chronic lung disease of infancy
  • Congenital diaphragmatic hernia

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Looking beyond PPHN : The unmet challenge of chronic progressive pulmonary hypertension in the newborn. / Fike, Candice D.; Aschner, Judy L.

In: Pulmonary Circulation, Vol. 3, No. 3, 01.09.2013, p. 454-466.

Research output: Contribution to journalReview article

@article{abcc6384f6e54381a3d61e316e027855,
title = "Looking beyond PPHN: The unmet challenge of chronic progressive pulmonary hypertension in the newborn",
abstract = "Infants with forms of pulmonary hypertension (PH) that persist or develop beyond the first week of life are an understudied group of patients with up to 40{\%}–60{\%} mortality. The clinical management of the progressive PH that develops in these infants is challenging because of the nonspecific signs and symptoms of clinical presentation, the limited diagnostic sensitivity of standard echocardiographic techniques, and the lack of proven therapies. The signaling mechanisms that underlie the structural and functional abnormalities in the pulmonary circulation of these infants are not yet clear. The ability to improve outcomes for these patients awaits technological advances to improve diagnostic capabilities and therapeutic discoveries made in basic science laboratories that can be tested in randomized clinical trials.",
keywords = "Bronchopulmonary dysplasia, Chronic lung disease of infancy, Congenital diaphragmatic hernia",
author = "Fike, {Candice D.} and Aschner, {Judy L.}",
year = "2013",
month = "9",
day = "1",
doi = "10.1086/674438",
language = "English (US)",
volume = "3",
pages = "454--466",
journal = "Pulmonary Circulation",
issn = "2045-8932",
publisher = "University of Chicago Press",
number = "3",

}

TY - JOUR

T1 - Looking beyond PPHN

T2 - The unmet challenge of chronic progressive pulmonary hypertension in the newborn

AU - Fike, Candice D.

AU - Aschner, Judy L.

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Infants with forms of pulmonary hypertension (PH) that persist or develop beyond the first week of life are an understudied group of patients with up to 40%–60% mortality. The clinical management of the progressive PH that develops in these infants is challenging because of the nonspecific signs and symptoms of clinical presentation, the limited diagnostic sensitivity of standard echocardiographic techniques, and the lack of proven therapies. The signaling mechanisms that underlie the structural and functional abnormalities in the pulmonary circulation of these infants are not yet clear. The ability to improve outcomes for these patients awaits technological advances to improve diagnostic capabilities and therapeutic discoveries made in basic science laboratories that can be tested in randomized clinical trials.

AB - Infants with forms of pulmonary hypertension (PH) that persist or develop beyond the first week of life are an understudied group of patients with up to 40%–60% mortality. The clinical management of the progressive PH that develops in these infants is challenging because of the nonspecific signs and symptoms of clinical presentation, the limited diagnostic sensitivity of standard echocardiographic techniques, and the lack of proven therapies. The signaling mechanisms that underlie the structural and functional abnormalities in the pulmonary circulation of these infants are not yet clear. The ability to improve outcomes for these patients awaits technological advances to improve diagnostic capabilities and therapeutic discoveries made in basic science laboratories that can be tested in randomized clinical trials.

KW - Bronchopulmonary dysplasia

KW - Chronic lung disease of infancy

KW - Congenital diaphragmatic hernia

UR - http://www.scopus.com/inward/record.url?scp=84907875003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907875003&partnerID=8YFLogxK

U2 - 10.1086/674438

DO - 10.1086/674438

M3 - Review article

AN - SCOPUS:84907875003

VL - 3

SP - 454

EP - 466

JO - Pulmonary Circulation

JF - Pulmonary Circulation

SN - 2045-8932

IS - 3

ER -